Prospects for Expanding the Possibilities of Etiotropic Therapy of Acute Respiratory Viral Infections in Primary School Children

   The aim of the study was to evaluate the efficacy and safety of the drug riamilovir (Triazavirin®), 100 mg capsules, in children aged 6–11 years with a diagnosis of acute respiratory viral infection (ARVI).

   Materials and methods. The multicenter study included 260 patients diagnosed with acute respiratory viral infections (ICD-10 codes: J00, J02, J02.9, J04, J04.0, J04.1, J04.2, J06, J06.0, J06.9), confirmed by polymerase chain reaction, in the presence of clinical manifestations. Patients were included in the study after one of their legal representatives and the patient themself (from the age of 10) signed an informed consent to participate in the study. The interval between the appearance of the first symptoms of the disease and the patient's inclusion in the study did not exceed 36 hours.

   Results. As a result of a multicenter, randomized, double-blind, comparative, placebo-controlled clinical trial, the efficacy and safety of treatment with riamilovir (Triazavirin®) in children aged 6–11 years with a diagnosis of acute respiratory viral infections were established. A decrease in the duration of the disease was shown when using the drug riamilovir compared with the control group. No serious adverse events were detected during the study.

   Conclusion. A multicenter clinical trial has established the high efficacy, safety, and good tolerability of riamilovir in the treatment of primary school-age children (6–11 years old) diagnosed with acute respiratory viral infections. The use of riamilovir in clinical practice as an etiotropic therapy in children aged 6–11 years with a diagnosis of acute respiratory viral infections is recommended due to its high efficacy and safety.

1. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federatsii v 2023 godu : Gosudarstvennyj doklad. Moskva: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka. 2024; 364. ISBN 978-5-7508-2132-7. (in Russian)

2. Klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii. Ostraya respiratornaya virusnaya infektsiya (ORVI) u detej. Proekt. https://ipoeasid.ru/wp-content/uploads/2022/05/ORVI-deti-EAOIB-NASIB.pdf. Ssylka aktivna na 12. 02. 2025. (in Russian)

3. Ostraya respiratornaya virusnaya infektsiya (ORVI). Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii. Moscow: 2022. Rezhim dostupa: https://cr.minzdrav.gov.ru/preview-cr/25_2. Ssylka aktivna na 12. 02. 2025. (in Russian)

4. WHO. Global Health estimates. Available at: https://www.who.int/ru/health-topics/vaccines-and-immunization/3#tab=tab_1. Accessed: 12. 02. 2025 (in Russian)]

5. Danilenko D. M., Sominina A. A., Komissarov A. B. et al. Influenza Vaccine effectiveness assessed at different stages of the epidemic cycle in reducing the frequency of hospitalization with influenza. Epidemiology and Vaccinal Prevention. 2019; 18 (5): 63–69. (in Russian)

6. O vnesenii izmenenii v prikaz Ministerstva zdravookhraneniia Rossiiskoi Federatsii ot 6 dekabria 2021 g. № 1122n «Ob utverzhdenii natsional'nogo kalendaria profilakticheskikh privivok, kalendaria profilakticheskikh privivok po epidemicheskim pokazaniiam i poriadka provedeniia profilakticheskikh privivok» : prikaz № 677n ot 12. 12. 2023. Available at: http://publication. pravo.gov.ru/document/0001202401300021. Accessed: 12. 02. 2025 (in Russian)

7. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 6 dekabrya 2021 g. (red. Ot 12. 12. 2023 g) № 1122n «Ob utverzhdenii natsional'nogo kalendarya profilakticheskikh privivok, kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam i poryadka provedeniya profilakticheskikh privivok». Rezhim dostupa: http://publication.pravo.gov.ru/document/0001202112200070. Ssylka aktivna na 12. 02. 2025. (in Russian)

8. Interv'jyu rukovoditelya Rospotrebnadzora Anny Popovoj o glavnykh biologicheskikh ugrozakh. https://www.rospotrebnadzor.ru/press_service/publications/?ELEMENT_ID=12905&sphrase_id=4402603 Ssylka aktivna na 12. 02. 2025. (in Russian)

9. Kupchenko A. N., Ponezheva Zh. B. Sovremennye printsipy diagnostiki i lecheniya ORVI. Arkhiv# vnutrennej meditsiny. 2016; 1 (27). https://cyberleninka.ru/article/n/sovremennye-printsipy-diagnostiki-i-lecheniya-orvi/viewer. Ssylka aktivna na 12. 02. 2025. (in Russian)

10. Radtsig E. Jyu. i dr. Vospalitel'nye zabolevaniya lororganov kak oslozhnenie ORVI i grippa u detej. Rossijskaya otorinolaringologiya. 2013; 5 (66): 145–149. (in Russian)

11. Ostraya respiratornaya virusnaya infektsiya (ORVI). Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii. Moscow: 2022. Rezhim dostupa: https://cr.minzdrav.gov.ru/preview-cr/25_2. Ssylka aktivna na 12. 02. 2025. (in Russian)

12. Klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii. Ostraya respiratornaya virusnaya infektsiya (ORVI) u detej. Proekt. https://ipoeasid.ru/wp-content/uploads/2022/05/ORVI-deti-EAOIB-NASIB.pdf. Ssylka aktivna na 12. 02. 2025. (in Russian)

13. Ostraya respiratornaya virusnaya infektsiya (ORVI). Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii. Moscow: 2022. Rezhim dostupa: https://cr.minzdrav.gov.ru/view-cr/724_1. Ssylka aktivna na 12. 02. 2025. (in Russian)

14. Gosudarstvennyj reestr lekarstvennykh sredstv Rossijskoj federatsii. Instruktsiya po meditsinskomu primenenijyu. https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=riamilovir&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&regtype=1%2c6&pageSize=10&token=ffcc47aa-11f0-4fd4-9378-3b96dd2bb660&order=Registered&orderType=desc&page-Num=1. Ssylka aktivna na 12. 02. 2025. (in Russian)

15. Sabitov A. U., Kovtun O. P., Batskalevich N. A., Maltsev O. V., Zhdanov K. V., Esaulenko E. V., Tikhonova E. P., Kalinina Yu. S., Sorokin P. V., Chepur S. V., Stepanov A. V. Meta-analysis of randomized controlled clinical trials of Riamilovir efficacy in the etiotropic therapy of acute respiratory viral infection. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2021; 66: 5–6: 48–57. doi: 10.37489/0235-2990-2021-66-5-6-48-57. (in Russian)

16. Sabitov A. U., Kovtun O. P., Batskalevich N. A., Lvov N. I., Zhdanov K. V., Esaulenko E. V., Tikhonova E. P., Kalinina Yu.S., Sorokin P. V., Chepur S. V., Stepanov A. V. Meta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2021; 66: 5–6: 58–71. doi: 10.24411/0235-2990-2021-66-5-6-58-71. (in Russian)

17. Kozlov K. V., Mal'tsev O.V., Kas'yanenko K. V. et al. Otsenka profilakticheskoj effektivnosti nukleozidnogo analoga riamilovira v otnoshenii ORVI u lits iz organizovannogo kollektiva. Terapevticheskij Arkhiv. 2024; 96 (11): 1035–1041. (in Russian)

18. Pshenichnaya N.Jyu., Luzhetskaya A. A., Konnova Jyu.A. i dr. Opyt lecheniya tyazheloj likhoradki denge preparatom riamilovir. Infektsionnye Bolezni. 2024; 22 (2): 133–136. (in Russian)

19. Sabitov A. U., Lioznov D. A., Zhdanov K. V., Tikhonova E. P., Esaulenko E. V., Sorokin P. V. Rezul'taty randomizirovannogo dvojnogo slepogo mnogotsentrovogo klinicheskogo issledovaniya effektivnosti i bezopasnosti primeneniya preparata riamilovir dlya profilaktiki SOVID-19. Terapevticheskij Arkhiv. 2024; 96 (3): 229–234. doi: 10.26442/00403660.2024.03.202652. (in Russian)

20. Sabitov A. U., Lioznov D. A., Zhdanov K. V., i dr. Rezul'taty randomizirovannogo dvojnogo slepogo mnogotsentrovogo klinicheskogo issledovaniya effektivnosti i bezopasnosti preparata riamilovira v terapii COVID-19. Terapevticheskij Arkhiv. 2024; 96 (5): 515–520. doi: 10.26442/00403660.2024.05.202770. (in Russian)

21. Sabitov A. U., Kovtun O. P., Esaulenko E. V., Sorokin P. V. Novyj podkhod k etiotropnoj terapii ORVI u detej. Terapevticheskij arkhiv. 2022; 94 (11): 1278–1284. https://ter-arkhiv.ru/0040-3660/article/view/119966. Ssylka aktivna na 12. 02. 2025. (in Russian)